Table 2.
Clinical characteristics of 231 cases of syphilis.
| Characteristic | Syphilis cases (n = 231) |
|---|---|
| Previous history of syphilis | 101 (43.7) |
| Syphilis stage | |
| Earlya | 62 (26.8) |
| Late latent or unknown duration | 128 (55.4) |
| Neurosyphilis | 41 (17.8) |
| Median RPR titerb | |
| <1:16 | 28 (12.1) |
| 1:16 to 1:128 | 101 (43.7) |
| >1:128 | 102 (44.2) |
| Syphilis treatment | |
| Penicillin | 218 (94.4) |
| Ceftriaxone | 6 (2.6) |
| Doxycycline | 7 (3.0) |
| CD4 cell countb | |
| Median CD4 cell count, cells/mL (IQR) | 280 (118–454) |
| >200 cells/mL | 144 (62.3) |
| 50–200 cells/mL | 49 (21.2) |
| <50 cells/mL | 27 (11.7) |
| Unknown | 11 (4.8) |
| Median HIV RNA level, copies/mL (IQR)b | 8742 (322–79,860) |
| Antiretroviral therapy duration >6 monthsc | |
| Any antiretroviral therapy | 169 (73.2) |
| HAART | 142 (61.5) |
| Macrolide therapyc | |
| Any macrolide therapy | 80 (37.2) |
| Treatment duration >3 months | 52 (22.5) |
| Penicillin or doxycycline therapyc | 27 (11.7) |
NOTE. Data are no. (%) of cases, unless otherwise indicated. IQR, interquartile range; RPR, rapid plasma reagin.
a
Includes primary syphilis, secondary syphilis, and early latent syphilis.
b
At the time of syphilis diagnosis.
c
Any time during follow-up.